Notable Upgrades: Tesla Motors (TSLA), Avalanche Biotechnologies (AAVL), J. C. Penney (JCP), Kite Pharma (KITE), Mobileye N.V. (MBLY)

Analysts at Morgan Stanley (MS) raised their Tesla Motors, Inc. (TSLA) price target to $465 from $280 in a research report issued to clients on Monday.

TSLA is currently printing a higher than average trading volume with the issue trading 4.3 million shares, compared to the average volume of 3.6 million. The stock began trading this morning at $255.62 to currently trade 3.76% higher from the prior days close of $243.15. On an intraday basis it has gotten as low as $250.51 and as high as $256.58.

TSLA shares have declined 8.82% in the last 4 weeks and 2.29% in the past three months. Over the past 5 trading sessions the stock has gained 0.26%. The Palo Alto, California-based electric car maker, which is currently valued at $32.75 billion, has a median Wall Street price target of $289.

TSAL is down 6.97% year-over-year, compared with a 6.08% gain in the S&P 500.

Analysts at Chardan Capital Markets upgraded their rating on the shares of Avalanche Biotechnologies, Inc. (AAVL). In a research note published on Monday, the firm lifted the name with a ‘Buy‘ from ‘Neutral‘ rating and set a 12-month base case estimate at $17.50 per share.

On valuation measures, Avalanche Biotechnologies Inc. shares have a price/book and price/sales ratio of 0.95 and 262.99, respectively. EPS is ($1.69).

Currently, there are 3 analysts that rate AAVL a ‘Buy‘, 2 rate it a ‘Hold‘. No analyst rates it a ‘Sell‘. AAVL has a median Wall Street price target of $20.00 with a high target of $25.00.

In a report published Monday, B. Riley & Co. analysts initiated coverage on J. C. Penney Company, Inc. (JCP) with a ‘Buy‘ rating and $12.50 price target.

JCP shares recently gained $0.29 to $8.81. In the past 52 weeks, shares of Plano Texas-based company have traded between a low of $5.90 and a high of $11.30.

Shares are down 12.53% year-over-year ; up 31.48% year-to-date.

Shares of Kite Pharma, Inc. (KITE) are up 2.25, or 3.88%, at $60.25, after Standpoint Research analysts today initiated coverage of the name, giving it a ‘Buy‘ rating and price target of $100.

Kite Pharma shares have gained 161%  year-over-year and 0.57% since the beginning of the year. In the past 52 weeks, shares of Santa Monica, California-based biopharmaceutical firm have traded between a low of $21.67 and a high of $89.21.

Mobileye N.V. (MBLY) was reiterated a ‘Overweight’ by Morgan Stanley analysts on Monday. The firm also raised its price target on the stock to $80 from $68. The name hit a new all time high of $63.72 following Morgan’s new target.

Mobileye N.V. shares are currently priced at 1,371.74x this year’s forecasted earnings, which makes them quite expensive compared to the industry’s 16.38x earnings multiple. Ticker has a forward P/E of 84.99 and t-12 price-to-sales ratio of 75.06. EPS for the same period is $0.05.

In the past 52 weeks, shares of Jerusalem, Israel-based company have traded between a low of $32.41 and a high of $63.72 and are now at $63.10.

Shares are up 77.53% year-over-year and 47.07% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*